Pfizer (NYSE:PFE) Hits New 1-Year Low at $25.26

Pfizer Inc. (NYSE:PFE) reached a new 52-week low on Thursday . The company traded as low as $25.26 and last traded at $25.30, with a volume of 19767977 shares. The stock had previously closed at $25.42.

Analyst Ratings Changes

PFE has been the subject of a number of analyst reports. Argus cut Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. TD Cowen downgraded shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price objective on the stock. in a research note on Thursday, January 4th. Guggenheim began coverage on shares of Pfizer in a research note on Friday, February 23rd. They set a “buy” rating and a $36.00 price objective on the stock. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a research note on Monday. Twelve equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $36.88.

Pfizer Stock Down 0.1 %

The company has a market cap of $143.77 billion, a P/E ratio of 70.25, a P/E/G ratio of 1.16 and a beta of 0.61. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.91. The stock has a 50 day moving average price of $27.19 and a 200 day moving average price of $28.76.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.29. The business had revenue of $14.25 billion for the quarter, compared to analyst estimates of $14.37 billion. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The firm’s revenue for the quarter was down 41.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.14 EPS. Research analysts expect that Pfizer Inc. will post 2.24 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of PFE. Worth Asset Management LLC acquired a new position in shares of Pfizer during the first quarter worth approximately $29,000. Briaud Financial Planning Inc bought a new stake in shares of Pfizer in the third quarter valued at about $30,000. Main Street Group LTD bought a new stake in shares of Pfizer in the fourth quarter valued at about $30,000. GoalVest Advisory LLC lifted its stake in shares of Pfizer by 304.9% in the fourth quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 811 shares during the period. Finally, Creekmur Asset Management LLC acquired a new stake in Pfizer during the fourth quarter worth $32,000. Institutional investors own 68.36% of the company’s stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.